Hadassit’s Enlivex Therapeutics Closes $16.75M Registered Direct Offering
Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage immunotherapy company, today announced the closing of its previously announced registered direct offering to certain accredited and healthcare-focused institutional investors, including Armistice Capital,…
Continue Reading
Hadassit’s Enlivex Therapeutics Closes $16.75M Registered Direct Offering